J&J to buy psychiatric drug developer Intra-Cellular for $14.6B - BioPharma Dive
Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.
Search Group
Share To
Comments
About Screade
Screade® Inc. version f59620b, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments